Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rebody Health vs StackMD

Rebody Health
Graded #159

Higher grade

vs+4.300000000000004
StackMD
Graded #255

Lower grade

The verdict

Rebody Health takes it — 67.7/100 to 63.4/100.

Rebody Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
46
46
Dose & formulationRebody Health +34
88
54
Clinical oversightRebody Health +3
81
78
Labs & monitoringStackMD +9
53
62
FulfillmentStackMD +5
84
89
Contract termsStackMD +14
55
69
Rebody Health · left barStackMD · right bar

The numbers

MetricRebody HealthStackMD
WeighScore67.7/10063.4/100
GradeCC
Scorecard rank#159#255
Semaglutide$200/mo (starting dose, compounded)$125/mo (1 mg dose, plus a separate fee, compounded)
Tirzepatide$250/mo (starting dose, compounded)$199/mo (5 mg dose, compounded)
Coverage47 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Rebody Health

Graded #159 · C

Strengths

  • Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
  • Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
  • Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
  • Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
  • Names its operating company (Compound Technologies Inc.) and references LegitScript approval

Where it loses points

  • Individual compounding pharmacies are not named on the marketing site
  • Not available in Massachusetts, Rhode Island, or Vermont
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
StackMD

Graded #255 · C

Strengths

  • Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
  • Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
  • No membership or platform fee — the medication price is the whole price
  • States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility

Where it loses points

  • All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
  • Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
  • Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
  • Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
  • Terms impose binding arbitration in New York and waive jury trial and class-action participation

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard